B.Riley FBR Sticks to Its Buy Rating for Novavax

By Jason Carr

B.Riley FBR analyst George Zavoico reiterated a Buy rating on Novavax (NASDAQ: NVAX) on January 11 and set a price target of $10. The company’s shares closed yesterday at $1.61.

According to TipRanks.com, Zavoico is a 2-star analyst with an average return of 0.6% and a 43.9% success rate. Zavoico covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc, and Actinium Pharmaceuticals.

Currently, the analyst consensus on Novavax is Moderate Buy and the average price target is $4.83, representing a 200.0% upside.

In a report issued on January 11, Ladenburg also reiterated a Buy rating on the stock with a $2.50 price target.

Based on Novavax’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $8.35 million and GAAP net loss of $44.61 million. In comparison, last year the company earned revenue of $5.4 million and had a GAAP net loss of $57.11 million.

Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NVAX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Novavax, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the provision of development of recombinant nanoparticle vaccines and adjuvants. Its product pipeline targets infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus, seasonal influenza, pandemic influenza, and Ebola virus.